Skip to main content
SpringerLink
Log in

Neoadjuvant chemotherapy for primary breast cancer: Lessons learned and opportunities to optimize therapy

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kennedy BJ. Hormone therapy in inoperable breast cancer.Cancer 1969;24:1345–9.

    Article  PubMed  CAS  Google Scholar 

  2. Campbell FC, Morgan DA, Bishop HM, et al. The management of locally advanced carcinoma of the breast by Nolvadex (tamoxifen): a pilot study.Clin Oncol 1984;10:111–5.

    PubMed  CAS  Google Scholar 

  3. Bradbeer J. Treatment of primary breast cancer in elderly with “Novaldex” alone.Rev Endocrine-Related Cancer 1985;16:39–42.

    Google Scholar 

  4. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy.Cancer 1988;62:2507–16.

    Article  PubMed  CAS  Google Scholar 

  5. Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast.Ann Surg 1995;222:612–8.

    Article  PubMed  CAS  Google Scholar 

  6. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer.Cancer 1990;66:119–29.

    Article  PubMed  CAS  Google Scholar 

  7. Ragaz J, Baird R, Rebbeck P, Goldie J, Coldman A, Spinelli J. Neoadjuvant (preoperative) chemotherapy for breast cancer.Cancer 1985;56:719–24.

    Article  PubMed  CAS  Google Scholar 

  8. Vlastos G, Mirza NQ, Lenert JT, et al. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.Cancer 2000;88:1417–24.

    Article  PubMed  CAS  Google Scholar 

  9. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.Eur J Cancer 1994;30A:645–2.

    Article  PubMed  CAS  Google Scholar 

  10. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast.N Engl J Med 1981;305:6–11.

    Article  PubMed  CAS  Google Scholar 

  11. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer.N Engl J Med 1985;312:665–73.

    Article  PubMed  CAS  Google Scholar 

  12. Bonnefoi H, Diebold-Berger S, Therasse P, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?Ann Oncol 2003;14:406–13.

    Article  PubMed  CAS  Google Scholar 

  13. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.J Clin Oncol 2000;18:1676–88.

    PubMed  CAS  Google Scholar 

  14. Deleted in proof.

  15. Clark J, Rosenman J, Cance W, Halle J, Graham M. Extending the indications for breast-conserving treatment to patients with locally advanced breast cancer.Int J Radiat Oncol biol Phys 1998;42:345–50.

    Article  PubMed  CAS  Google Scholar 

  16. Schwartz GF, Birchansky CA, Kornarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast.Cancer 1994;73:362–9.

    Article  PubMed  CAS  Google Scholar 

  17. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.J Clin Oncol Feb 1995;13:424–9.

    PubMed  CAS  Google Scholar 

  18. Wolmark N, Wang J, Mamounas EP, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national Surgical Adjuvant Breast and Bowel Project B-18.J Natl Cancer Inst Monographs 2001;30:96–102.

    PubMed  Google Scholar 

  19. Oruwari JU, Chung MA, Koelliker S, Steinhoff MM, Cady B. Axillary staging using ultrasound-guided fine needle aspiration biopsy in locally advanced breast cancer.Am J Surg 2002;184:307–9.

    Article  PubMed  Google Scholar 

  20. Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging.Cancer 1996;78:91–100.

    Article  PubMed  CAS  Google Scholar 

  21. Drew PJ, Kerin MJ, Mahapatra T, et al. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast.Eur J Surg Oncol 2001;27:617–20.

    Article  PubMed  CAS  Google Scholar 

  22. Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.Ann Surg Oncol 2001;8:549–59.

    Article  PubMed  CAS  Google Scholar 

  23. Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.Br J Cancer 2000;83:1480–7.

    Article  PubMed  CAS  Google Scholar 

  24. Kaplan E, Yu E, Tripathy D, et al. MRI patterns predict ability to perform breast conservation following neoadjuvant therapy for locally advanced breast cancer.Breast Cancer Res Treat 2003; 82(Suppl 1):S190.

    Google Scholar 

  25. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor.Cancer Res 1979;39:3861–5.

    PubMed  CAS  Google Scholar 

  26. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases.Cancer Res 1983;43:1488–92.

    PubMed  CAS  Google Scholar 

  27. Buchholz TA, Tucker SL, Masullo L, et al. Predictors of localregional recurrence after neoadjuvant chemotherapy and mastectomy without radiation.J Clin Oncol 2002;20:17–23.

    Article  PubMed  CAS  Google Scholar 

  28. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 1998;16:2672–85.

    PubMed  CAS  Google Scholar 

  29. Schwartz GF, Cantor RI, Biermann WA. Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast.Arch Surg 1987;122:1430–4.

    PubMed  CAS  Google Scholar 

  30. Partridge SC, Gibbs J, Lu Y, Esserman L, Sudilovsky D, Hylton N. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.Am J Roentgenol 2002;179:1193–9.

    Google Scholar 

  31. Makris, A, Powles TJ, Kakolyris S, Dowsett M, Ashley SE, Harris AL. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma.Cancer 1999; 85:1996–2000.

    PubMed  CAS  Google Scholar 

  32. Merajver SD, Weber BL, Cody R, et al. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience.J Clin Oncol 1997;15:2873–81.

    PubMed  CAS  Google Scholar 

  33. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.J Clin Oncol 1995;13:547–52.

    PubMed  CAS  Google Scholar 

  34. Semiglazov VF, Topuzov EE, Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer.Ann Oncol 1994;5:591–5.

    PubMed  CAS  Google Scholar 

  35. Green M, Hortobagyi GN. Neoadjuvant chemotherapy for operable breast cancer.Oncology 2002;16:871–84, 889; discussion, 889–90, 892–4, 897–8.

    PubMed  Google Scholar 

  36. Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer predictors of breast-conservation therapy feasibility.Ann Surg Oncol 2002;9:228–34.

    Article  PubMed  Google Scholar 

  37. Scholl SM, Pierga JY, Asselain B, et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.Eur J Cancer 1995;31A:1969–75.

    Article  PubMed  CAS  Google Scholar 

  38. Kuerer HM, Singletary SE, Buzdar AU, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma.Am J Surg 2001;182:601–8.

    Article  PubMed  CAS  Google Scholar 

  39. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docextaxel.J Clin Oncol 2002;20:1456–66.

    Article  PubMed  CAS  Google Scholar 

  40. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.J Clin Oncol 1999; 17:3412–7.

    PubMed  CAS  Google Scholar 

  41. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel (P) followed by FAC in the neoadjuvant setting provides improved pathologic complete remission rates (pCR) compared to standard paclitaxel followed by FAC therapy: Preliminary results of an ongoing prospective clinical trial (abstract 129).Proc Am Soc Clin Oncol 2001;20:33a.

    Google Scholar 

  42. Hutcheon AW, Ogston KN, Heys SD, et al. Primary chemotherapy in the treatment of breast cancer: Significantly enhanced clinical and pathological response with docetaxel (abstract 317).Proc Am Soc Clin Oncol 2000;19:83a.

    Google Scholar 

  43. Eremin O, Walker LG, Smith IC, et al. Chemotherapy in breast cancer: enhanced response with docetaxel (abstract 271.Proc Am Soc Clin Oncol 1999;18:72a.

    Google Scholar 

  44. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.J Clin Oncol 2003;21:976–83.

    Article  PubMed  CAS  Google Scholar 

  45. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.J Clin Oncol 2003;21:4165–74.

    Article  PubMed  CAS  Google Scholar 

  46. Goble S, Bear HD. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.Surg Clin North Am 2003;83:943–71.

    Article  PubMed  Google Scholar 

  47. Hutcheon AW, Heys SD, Sarkar TK. Neoadjuvant docetaxel in locally advanced breast cancer.Breast Cancer Res Treat 2003;79 (Suppl 1):S19–24.

    Article  Google Scholar 

  48. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.Clin Breast Cancer 2002;3(Suppl 2):S69–74.

    Article  Google Scholar 

  49. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.J Natl Cancer Inst 1990;82:1539–45.

    PubMed  CAS  Google Scholar 

  50. Daidone MG, Veneroni S, Benini E, et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer.Int J Cancer 1999;84:580–6.

    Article  PubMed  CAS  Google Scholar 

  51. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome.Br J Cancer 2003;88:406–12.

    Article  PubMed  CAS  Google Scholar 

  52. Gregory RK, Powles TJ, Salter J, Chang JC, Ashley S, Dowsett M. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy.Breast Cancer Res Treat 2000;59:171–5.

    Article  PubMed  CAS  Google Scholar 

  53. Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.Br J Cancer 1978;77:621–6.

    Google Scholar 

  54. Schwartz GF, Birchansky CA, Komanicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast.Cancer 1994;73:362–9.

    Article  PubMed  CAS  Google Scholar 

  55. Esserman L, Sudilovsky D, Kuo W-I, Gray J, Hylton N. Response to neoadjuvant therapy for breast cancer by magnetic resonance imaging type, estrogen receptor status, grade, and comparative genomic hybridization (abstract 235).Breast Cancer Res Treat 2001;69:245.

    Google Scholar 

  56. Partridge, S, Gibbs J, Lu Y, Esserman L, Hylton N. MRI measurements of tumor volume and vascularity are valuable prognostic indicators for monitoring neoadjuvant chemotherapy of breast cancer (abstract 609).Breast Cancer Res Treat 2002;76(Suppl 1):S150.

    Google Scholar 

  57. Yu EW, Hylton N, Partridge S, et al. MR imaging phenotypes predict response and recurrence in locally advanced breast cancer treated with neoadjuvant chemotherapyBreast Cancer Res Treat 2003;82(Suppl 1):S69.

    Google Scholar 

  58. Ramaswamy S, Perou CM. DNA microarrays in breast cancer: the promise of personalised medicine.Lancet 2003;361(9369):1576–7.

    Article  PubMed  Google Scholar 

  59. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci U S A 2001;98:10869–74.

    Article  PubMed  CAS  Google Scholar 

  60. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer.N Engl J Med 2002;347:1999–2009.

    Article  PubMed  Google Scholar 

  61. Esserman L, Miller ID, Tripathy D, et al. Are some patients cured after local therapy alone? Clues based on the natural history data from Turku Finland (abstract 142).Breast Cancer Res Treat 2002; 76:S48.

    Google Scholar 

Download references

Author information

Author notes

  1. Laura Esserman MD, MBA (Director)

    Present address: Carol Franc Buck Breast Care Center, University of California San Francisco Medical Center, 1600 Divisadero, Floor 2, Box 1710, 94115, San Francisco, CA

Authors and Affiliations

  1. Department of Surgery and Radiology, University of California San Francisco Medical Center, San Francisco, California

    Laura Esserman MD, MBA (Director)

Authors
  1. Laura Esserman MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Esserman, L. Neoadjuvant chemotherapy for primary breast cancer: Lessons learned and opportunities to optimize therapy. Annals of Surgical Oncology 11 (Suppl 1), 3S–8S (2004). https://doi.org/10.1007/BF02524789

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02524789

Keywords

Search

Navigation